ENHANCE-2: A study for individuals with untreated TP53 mutant acute myeloid leukemia (AML)

ENHANCE-2 is a clinical research study investigating magrolimab plus azacitidine versus venetoclax plus azacitidine or intensive chemotherapy in adults with previously untreated TP53 mutant AML.

Selected Eligibility Criteria

- 18+ years of age or older
- Previously untreated AML with at least one TP53 mutation that is not benign
- No prior treatment with CD47- or SIRPα-targeting agent or with antileukemic therapy (excluding hydroxyurea or oral etoposide)

If you are interested in participating in ENHANCE-2 and meet these criteria, please ask your doctor about your eligibility and further details about the study.

Visit ClinicalTrials.gov and search NCT04778397 for more information.

The safety, efficacy and uses of magrolimab have not been established. There is no guarantee that magrolimab will be approved by the FDA or other global health authorities in AML.